Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 7/20 | 0.53 |
| ▸ | PIM1 | P11309 | 3/20 | 0.53 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.53 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.53 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.53 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.53 |
| ▸ | GUSB | P08236 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 2/20 | 0.51 |
| ▸ | BRD1 | O95696 | 1/20 | 0.51 |
| ▸ | BRD2 | P25440 | 1/20 | 0.51 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL348454 | 0.87 | BRD4 (0.54) | BRD4PARP1BRD1BRD2HDAC3 | |
| SCHEMBL17889921 | 0.86 | BRD4 (0.53) | BRD4PARP1BRD1BRD2PDE7A | |
| SCHEMBL20811757 | 0.86 | BRD4 (0.53) | BRD4PARP1BRD1BRD2HDAC3 | |
| SCHEMBL17889913 | 0.81 | AMY1A (0.58) | BRD4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL346832 | 0.79 | BRD4 (0.52) | BRD4GUSBPARP1BRD1BRD2 | |
| SCHEMBL149248 | 0.79 | BRD4 (0.67) | BRD4GUSBPARP1BRD1BRD2 | |
| SCHEMBL30434465 | 0.79 | BRD4 (0.67) | BRD4GUSBPARP1BRD1BRD2 | |
| SCHEMBL349223 | 0.79 | NPC1 (0.59) | BRD4PARP1BRD1BRD2HDAC3 | |
| SCHEMBL17796054 | 0.79 | AMY1A (0.58) | BRD4PARP1BRD1BRD2HDAC3 | |
| SCHEMBL348295 | 0.78 | BRD4 (0.70) | BRD4PARP1BRD1BRD2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180104245-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2018-04-19 | — | — | US | claimed |
| US-20130281397-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | claimed |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | HEPALINK (HONG KONG) LIMITED (HK) | 2008-08-07 | — | — | US | claimed |
| US-20210361656-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2021-11-25 | — | — | US | disclosed |
| US-20210361656-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2021-11-25 | — | — | US | disclosed |
| US-20200352946-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. | 2020-11-12 | — | — | US | disclosed |
| US-20200352946-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. | 2020-11-12 | — | — | US | disclosed |
| US-20180104245-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2018-04-19 | — | — | US | disclosed |
| US-20180104245-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2018-04-19 | — | — | US | disclosed |
| US-20180104245-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2018-04-19 | — | — | US | disclosed |
| US-20160346291-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR ACCELERATED PLAQUE REGRESSION | RESVERLOGIX CORP (CA) | 2016-12-01 | — | — | US | disclosed |
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. | 2012-01-19 | — | — | US | disclosed |
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. | 2012-01-19 | — | — | US | disclosed |
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. | 2012-01-19 | — | — | US | disclosed |
| US-8053440-B2 | Compounds for the prevention and treatment of cardiovascular diseases | Resverlogix Corporation (CA) | 2011-11-08 | — | — | US | disclosed |
| US-8053440-B2 | Compounds for the prevention and treatment of cardiovascular diseases | Resverlogix Corporation (CA) | 2011-11-08 | — | — | US | disclosed |
| US-8053440-B2 | Compounds for the prevention and treatment of cardiovascular diseases | Resverlogix Corporation (CA) | 2011-11-08 | — | — | US | disclosed |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | HEPALINK (HONG KONG) LIMITED (HK) | 2008-08-07 | — | — | US | disclosed |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | HEPALINK (HONG KONG) LIMITED (HK) | 2008-08-07 | — | — | US | disclosed |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | HEPALINK (HONG KONG) LIMITED (HK) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180104245-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | BRD4 1910/4885PIM1 3738/4885CSNK2A2 2551/4885 |
| US-20130281397-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | BRD4, BMI1, BRPF3 | BRD4 1/4885PIM1 592/4885CSNK2A2 2193/4885 |
| US-20160346291-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR ACCELERATED PLAQUE REGRESSION | PCSK9, TGFB1, HMGCR | BRD4 3081/4885PIM1 526/4885CSNK2A2 531/4885 |
| US-20210361656-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | BRD4 1910/4885PIM1 3738/4885CSNK2A2 2551/4885 |
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | BRD4 1910/4885PIM1 3738/4885CSNK2A2 2551/4885 |
| US-20200352946-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | BRD4 1910/4885PIM1 3738/4885CSNK2A2 2551/4885 |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | APOB, LDLR, APOL1 | BRD4 693/4885PIM1 4280/4885CSNK2A2 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.